Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.53 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495147 | 0.90 | PYGM (0.67) | PYGMP2RY6P2RY14TK1NT5E | |
| Fialuridine SCHEMBL21551995 | 0.87 | PYGM (0.69) | PYGMP2RY6P2RY14TK1 | |
| SCHEMBL21551984 | 0.85 | PYGM (0.53) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL8815214 | 0.84 | PYGM (0.61) | PYGMP2RY6P2RY14TK1 | |
| SCHEMBL8815220 | 0.84 | PYGM (0.61) | PYGMP2RY6P2RY14TK1 | |
| Fialuridine SCHEMBL24359134 | 0.83 | PYGM (0.77) | PYGMP2RY6P2RY14TK1 | |
| Fialuridine SCHEMBL20769829 | 0.83 | PYGM (0.77) | PYGMP2RY6P2RY14TK1 | |
| Fialuridine SCHEMBL773510 | 0.83 | PYGM (0.77) | PYGMP2RY6P2RY14TK1 | |
| Fialuridine SCHEMBL9059414 | 0.83 | PYGM (0.77) | PYGMP2RY6P2RY14TK1 | |
| Fialuridine SCHEMBL3084382 | 0.83 | PYGM (0.77) | PYGMP2RY6P2RY14TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983077-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | Alnylam Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3790970-A1 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020257194-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2019217459-A1 | EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |